CLAIM #56496 · Thermo Fisher Scientific Inc (TMO) · 2024Q4 earnings call · Jan 30, 2025 · due Dec 31, 2026
“It bodes really well for the acceleration of growth, certainly in 2026 and beyond.”
Marc Casper · CEO
CANNOT_DETERMINE
resolved by a revision, graded at the moved level · official band 5 percent
Committed
It bodes really well for the acceleration of growth, certainly in 2026 and beyond.
Reported
This would lead to a 2026 and 2027 scenario where we will deliver 3% to 6% organic revenue growth.
How to check this claim
Look at: Company-reported organic/total revenue growth rate, fiscal year 2026
It came true if: FY2026 revenue growth rate higher than FY2025 reported growth rate
Where: Company income statement / annual report and earnings release (FY2026 results)
Verify independently
SEC filings for TMO ↗ · Claim quote is verbatim from the 2024Q4 earnings call.